Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Stomach Neoplasms 1Skin Neoplasms 1Neoplasm Recurrence, Local 1Neoplasm Metastasis 1Lung Neoplasms 1Liver Neoplasms 1Kidney Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 40Cisplatin 25Fluorouracil 24Paclitaxel 21Oxaliplatin 16Capecitabine 12Leucovorin 10Irinotecan 10Docetaxel 10Gemcitabine 8Carboplatin 7atezolizumab 6Nivolumab 6Bevacizumab 6Trastuzumab 5Ramucirumab 5Radiotherapy 5spartalizumab 4Albumin-Bound Paclitaxel 4zanidatamab 3tisotumab vedotin 3patritumab deruxtecan 3lenvatinib 3fludarabine 3durvalumab 3Radiation 3Drug Therapy 3Cyclophosphamide 3130-nm albumin-bound paclitaxel 3zimberelimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Esophageal Neoplasms × Poly I-C × Clear all
NCT00094003 2005-11-11

Study of NS-9 in Patients With Liver Metastases

NS Pharma, Inc.

Phase 1 Completed
20 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Esophageal Neoplasms, Kidney Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Neoplasm Recurrence, Local, Skin Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡